Bengaluru: The U.S. Food and Drug Administration issued 25 warning letters to telehealth companies for marketing false and misleading claims about compounded versions of Eli Lilly and Novo Nordisk's hugely popular weight loss and diabetes drugs.
The letters, that were posted on the health regulator's website on Tuesday, were sent to companies like Medica Weight Loss, Ready Med, Clover Meds among others earlier this month.
The health regulator previously sent a series of warning letters to telehealth firms as part of its broader crackdown on compounded drugs.
Some telehealth companies claimed on their websites that their compounded versions of Lilly's tirzepatide and Novo's semaglutide were sourced from FDA approved pharmacies or were the ingredients were clinically studied, the regulator said in the letters.
For others, the agency noted the representations made by the telehealth firms regarding compounded semaglutide and tirzepatide products are false or misleading. Some companies made claims that their compounded products were the same as approved GLP-1 drugs or displayed their products in a way which showed they compounded the drugs.Lilly's tirzepatide is the active ingredient obesity injection Zepbound and its diabetes drug Mounjaro, while semaglutide is used in the Danish drugmaker's diabetes drug Ozempic and weight-loss drug Wegovy.
"Patients deserve to know what they're getting - compounded GLP-1 products have not been proven safe, effective, or of consistent...
False. The quotes attributed to the politicians have been fabricated by a foreign-run disinformation operation. AAP FactCheck - Pauline Hanson and Anthony Albanese did not trade barbs during a liv...